| Patient | Nelson Mandela |
|---|---|
| Date of birth | 1943-07-18 |
| Identifiers | MRN HR-ML021-SYN; SSN (made up) 000-21-6718 |
| Document date | 2026-10-27 |
| Author | Thandiwe Mokoena, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Follow-up six weeks after radiotherapy for prostate cancer. [S]
Mr. Mandela returns six weeks after finishing 37 fractions of radiotherapy, which he completed without a break. In the fourth week he developed urinary frequency, a weaker stream, and getting up twice a night, and radiation oncology started tamsulosin 0.4 mg in the evening; these symptoms are now improving, and he has had no burning, blood in the urine, or retention, and no dizziness on standing. In the last weeks of treatment his bowels became looser, two or three times a day with some urgency, and they are now settling to once or twice a day, with no bleeding. Asked about his bowels before treatment, he says they were regular, about once a day, as recorded at his wellness visit. His second leuprolide depot ran out about three weeks ago; hot flashes are fewer, and the tiredness he had during radiotherapy is lifting. His mood is good. He has resumed his morning walks. [S]
| Element | Detail |
|---|---|
| Radiotherapy | 74 Gy in 37 fractions, completed six weeks ago |
| Urinary | Frequency and nocturia twice, improving on tamsulosin; no blood or burning |
| Bowel | Looser stools and mild urgency, settling; no bleeding |
| Androgen deprivation | Completed; last depot ran out three weeks ago; hot flashes fading |
| System | Result | Finding |
|---|---|---|
| Constitutional | Positive | Tiredness from radiotherapy, improving; weight stable |
| Genitourinary | Positive | Frequency and nocturia twice, improving; no burning, blood, or retention |
| Gastrointestinal | Positive | Stools once or twice a day, softer than before, with mild urgency; no bleeding |
| Endocrine | Positive | Occasional hot flashes, fewer than before |
| Neurological | Negative | No dizziness on standing |
| Psychiatric | Negative | Mood good; PHQ-2 score 0 |
6 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Bicalutamide 50 mg oral tablet, one tablet by mouth once daily for four weeks, to block the testosterone flare at the start of leuprolide | One tablet once daily for four weeks | Oral route | 2026-04-14 to 2026-05-12 | completed | S |
| Leuprolide acetate 22.5 mg injection (three-month depot), intramuscular, two doses twelve weeks apart (the second given at a primary care visit), about six months of androgen deprivation with radiotherapy | One injection every twelve weeks, two doses | Intramuscular route | 2026-04-21 to 2026-10-06 | completed | S |
| Cholecalciferol (vitamin D3) 1000 units oral tablet, one tablet by mouth once daily | One tablet once daily | Oral route | 2026-04-14 | active | S |
| Tamsulosin 0.4 mg oral capsule, one capsule by mouth once daily after the evening meal, for urinary frequency during radiotherapy | One capsule once daily in the evening | Oral route | 2026-08-18 | active | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-10-27 | Body height | 183 | cm | S |
| 2026-10-27 | Body weight | 81.4 | kg | S |
| 2026-10-27 | Body mass index (BMI) [Ratio] | 24.3 | kg/m2 | S |
| 2026-10-27 | Systolic blood pressure | 128 | mm[Hg] | S |
| 2026-10-27 | Diastolic blood pressure | 74 | mm[Hg] | S |
| 2026-10-27 | Heart rate | 68 | /min | S |
| 2026-10-27 | Respiratory rate | 14 | /min | S |
| 2026-10-27 | Body temperature | 36.7 | Cel | S |
| 2026-10-27 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-10-27 | Prostate specific Ag [Mass/volume] in Serum or Plasma | 0.4 | ng/mL | <=4 ng/mL | Normal | S |
| 2026-10-27 | Testosterone [Mass/volume] in Serum or Plasma | 38 | ng/dL | 264 to 916 ng/dL in adult men; below 50 ng/dL is the castrate target on androgen deprivation | Low | S |
| 2026-10-27 | International Prostate Symptom Score [IPSS] | 12 | {score} | S | ||
| 2026-10-27 | Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] | 0 | {score} | S |
Vital signs recorded on 2026-10-27; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Well |
| Cardiovascular | Regular rhythm; blood pressure 128/74 mm Hg seated; no ankle swelling |
| Abdomen | Soft and non-tender; bladder not palpable |
| Skin | Mild hyperpigmentation over the treated area only; skin intact |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Adenocarcinoma of the prostate, NCCN unfavorable intermediate risk: cT1c, Grade Group 3 (Gleason 4+3), PSA 6.4 ng/mL, 3 of 14 cores, found after a rising PSA; synthetic modern detail linked to his publicly announced prostate cancer | active | confirmed | C61 | S — Synthetic grade, PSA, core count, stage, and risk group; the PSA rise, the biopsy-proven localized cancer that was not high grade, hormone therapy, and curative radiotherapy are from his doctors' and spokeswoman's public statements (D). |
| Hormone-sensitive prostate cancer | active | confirmed | Z19.1 | S — Synthetic status in the modern episode. |
| Short-term androgen deprivation therapy (six months, leuprolide), with monitoring of testosterone, bone density, metabolic and cardiovascular risk, hot flashes, mood, and cognition | active | confirmed | Z79.899 | S — Synthetic androgen deprivation plan; Z79.899 is used because ICD-10-CM has no specific code for GnRH agonist therapy. |
| History of pulmonary tuberculosis, treated, with no symptoms since | resolved | confirmed | Z86.11 | S — The 1988 tuberculosis is documented (D); the coding and the statement that it has not recurred are synthetic. |
| Personal history of external beam radiotherapy to the prostate | active | confirmed | Z92.3 | S — Synthetic: recorded after the course of radiotherapy finished. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Laboratory | PSA after radiotherapy | Every 6 to 12 months for 5 years, then yearly | Completed today | 0.4 ng/mL, first value after radiotherapy; next in six months |
| Laboratory | Testosterone recovery | With PSA after androgen deprivation ends | Completed today | 38 ng/dL, not yet recovered |
| Laboratory | Hemoglobin A1c or fasting glucose, and lipid panel | Yearly after androgen deprivation | Due | Due in four months, one year after baseline |
| Imaging | Bone density (DXA) | Every 1 to 2 years after androgen deprivation | Up to date | Baseline six months ago; next in one to two years |
| Examination | Digital rectal examination | Yearly after curative treatment | Due | Not useful this soon after radiotherapy; due in one year |
| Examination | Blood pressure and cardiovascular assessment | Every visit while on androgen deprivation and after | Completed today | 128/74 mm Hg seated; no dizziness on standing on tamsulosin |
| Survey | Urinary symptoms (IPSS) | Every follow-up visit, particularly the first two years | Completed today | IPSS 12, up from 7 before treatment; improving on tamsulosin |
| Survey | Bowel function after radiotherapy | Every visit after radiotherapy | Completed today | Softer stools once or twice a day with mild urgency, settling; no bleeding |
| Survey | Bowel baseline missed before radiotherapy | Baseline before radiotherapy | Deferred | Not asked at the visit before radiotherapy, a deviation from the protocol. The wellness visit five weeks before that had recorded regular, formed stools once a day, and he confirms this today, so a baseline was available and no harm resulted. The bowel question is now on the pre-radiotherapy checklist |
| Survey | Sexual function | Periodically after treatment | Completed today | Reviewed; expected recovery after androgen deprivation explained; no treatment requested |
| Medication safety | Hot flashes and fatigue | Every visit until androgen deprivation effects resolve | Completed today | Fewer hot flashes; fatigue from radiotherapy improving |
| Survey | Distress and depression screen (PHQ-2) | At intervals | Completed today | PHQ-2 score 0 |
| Survey | Cognition | Periodically after androgen deprivation | Up to date | Mini-Cog 5 of 5 at the wellness visit; no change reported |
| Self-management | Survivorship care plan and lifestyle | After treatment; lifestyle every visit | Completed today | Written plan given; walking resumed; no tobacco |
Goal progress:
Immunizations given today: High-dose influenza vaccine, this season [S]
Guideline basis: NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer (2026); Eastham JA, et al. Clinically Localized Prostate Cancer: AUA/ASTRO Guideline, Part III: Principles of Radiation and Future Directions. J Urol 2022;208(1):26-33 (2022); Skolarus TA, et al. American Cancer Society prostate cancer survivorship care guidelines. CA Cancer J Clin 2014;64(4):225-249 (2014); CMID: Clinical Monitoring Intelligence Database, prostate cancer monograph (2026)
Follow-up: Primary care in three months to review tamsulosin and urinary and bowel symptoms. PSA and testosterone in six months. Radiation oncology review in six weeks, three months after treatment. Influenza vaccine given today. [S]